| Value | ₹2,750 Cr |
|---|
NSE filing, NSE: ABCAPITAL. Summary written from the filing by ALFA Finder's alert engine.
Aditya Birla Capital Ltd: key numbers
- Share price
- ₹356.00
- Market cap
- ₹97,473 Cr
- Revenue (annual)
- ₹45,509 Cr
- Net profit (annual)
- ₹3,764 Cr
- P/E (TTM)
- 23.8×Sector 21.4×
- Promoter holding
- 68.82%+0.01% QoQ
- FII holding
- 8.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aditya Birla Capital Ltd
All →Aditya Birla Capital Employee Stock Options
Aditya Birla Capital allotted 24,884 equity shares under its ESOP/RSU/PSU schemes on October 23, 2026. Paid-up capital increased to 27,38,00,66,370 shares of ₹10 each.
Aditya Birla Capital Debt & Borrowing
Aditya Birla Capital Limited fixed record dates for interest payments on various NCD series due in December 2026.
Aditya Birla Capital Other Announcement
Aditya Birla Capital Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations for the period ended September 30, 2026.
Aditya Birla Capital Board Meeting Date
Aditya Birla Capital Limited scheduled a board meeting for October 30, 2026, to consider and approve unaudited financial results for the half-year ended September 2026.
Aditya Birla Capital Debt & Borrowing: ₹118.7 Cr
Aditya Birla Capital paid Rs. 118.65 Crore interest on its NCD Series 'G1'. This filing fulfills the mandatory debt servicing disclosure.
- Value
- ₹118.7 Cr
Aditya Birla Capital Debt & Borrowing: ₹13.51 Cr
Aditya Birla Capital clarified the interest amount as ₹2.79 crore for its NCD series II, alongside confirming the ₹10.73 crore redemption payment.
- Value
- ₹13.51 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.